Who are ATRA and or Chemo as maintenance's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sohonos, TRIFAROTENE, Targretin, Panretin, Soriatane, Differin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atra-and-or-chemo-as-maintenance.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ATRA and or Chemo as maintenance — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ATRA and or Chemo as maintenance (ATRA and or Chemo as maintenance) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Retinoid; differentiation agent. Area: Oncology.

phase 3 Retinoid; differentiation agent Retinoic acid receptor alpha (RARα) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ATRA and or Chemo as maintenance (ATRA and or Chemo as maintenance) — Groupe d'etude et de travail sur les leucemies aigues promyelocytaires. ATRA (all-trans retinoic acid) induces differentiation of leukemic promyelocytes and promotes their maturation, often combined with chemotherapy to achieve complete remission in acute promyelocytic leukemia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ATRA and or Chemo as maintenance TARGET	ATRA and or Chemo as maintenance	Groupe d'etude et de travail sur les leucemies aigues promyelocytaires	phase 3	Retinoid; differentiation agent	Retinoic acid receptor alpha (RARα)
Sohonos	PALOVAROTENE	Ipsen	marketed	Retinoid [EPC]	Retinoic acid receptor gamma	2023-01-01
TRIFAROTENE	TRIFAROTENE		marketed	Retinoid [EPC]		2019-01-01
Targretin	BEXAROTENE	Bausch Health	marketed	Retinoid [EPC]	Retinoic acid receptor RXR-beta	1999-01-01
Panretin	ALITRETINOIN	Advanz	marketed	Retinoid [EPC]	Retinoic acid receptor beta	1999-01-01
Soriatane	ACITRETIN	Stiefel Labs Inc	marketed	Retinoid [EPC]	Bile salt export pump	1996-01-01
Differin	ADAPALENE	Galderma Labs Lp	marketed	Retinoid [EPC]	Retinoic acid receptor beta	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-09-15 — Differin · 8435502 · Formulation · US
2026-09-15 — Differin · 8709392 · Formulation · US
2028-05-31 — Differin · 7998467 · Formulation · US

Sponsor landscape (Retinoid; differentiation agent class)

Groupe d'etude et de travail sur les leucemies aigues promyelocytaires · 1 drug in this class
Mahmoud Ramadan mohamed Elkazzaz · 1 drug in this class
South China Children's Leukemia Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ATRA and or Chemo as maintenance — Competitive Intelligence Brief. https://druglandscape.com/ci/atra-and-or-chemo-as-maintenance. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab